Rx Medicare

As projected, Eli Lilly and Company (NYSE: LLY) has resubmitted its supplemental New Drug Application (sNDA) for Cymbalta(R) (duloxetine HCl) for the management of chronic pain to the U.S. Food and Drug Administration (FDA). Lilly’s resubmission is based on a recently completed study in chronic pain due to osteoarthritis, the extension phase of a chronic low back pain study and previously completed studies in pain due to osteoarthritis and chronic low back pain.

Read More…

Related Posts

• New Drug Application Submitted To FDA For Tapentadol Extended Release Tablets For Management Of Chronic Pain
• Cymbalta(R) Significantly Reduced Chronic Low Back Pain In New Study
• New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction On Cymbalta(R)
• Discovery That Active Ingredients In Marijuana Spread And Prolong Pain Has Implications For Medical Use Of Drug And Concepts Of Chronic Pain
• Xanodyne Receives Approval From The U.S. Food And Drug Administration For ZIPSOR(TM) (diclofenac Potassium) Liquid Filled Capsules
• Cadence Pharmaceuticals Submits Acetavance New Drug Application For The Treatment Of Acute Pain And Fever
• Pelvic Pain And Surgeries In Women Before Interstitial Cystitis/Painful Bladder Syndrome – Chronic Pelvic Pain, BPS And Pelvic Surgical Procedures
• Behavioral Problems In Childhood Double The Risk Of Chronic Widespread Pain In Adult Life
• Behavioral problems in childhood doubles the risk of chronic widespread pain in adult life
• Pediatricians Say Colleagues Cautious About Treating Chronic Pain In Children
• Non-drug techniques reduce pain in hospitalized patients
• MicroTransponder Raises $10 Million To Begin Clinical Trials Of Wireless Neurostimulation For Chronic Pain And Obtain FDA Clearance
• New, Targeted Pain Medicine Delivery Systems May Reduce Costs Long Term; Cost To Treat Pain Varies Significantly By Chronic Pain Condition
• New Treatment For Chronic Pain Condition
• FDA Approves Morphine Sulfate Oral Solution For Relief Of Acute And Chronic Pain

Tags: administration, application, chronic, cymbaltar, drug, food, lilly, pain, resubmits, supplemental

This entry was posted on Friday, June 5th, 2009 at 11:06 am and is filed under Analgesics Pain Migraine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.